Michael Higgins, Voyager interim CEO

No­var­tis takes a gam­ble on Voy­ager's new AAV tech, inks $1.7B gene ther­a­py dis­cov­ery pact

What­ev­er Voy­ager is com­ing up with on its new gene ther­a­py plat­form, No­var­tis wants a piece of it.

Voy­ager, which piv­ot­ed back in­to dis­cov­ery last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.